Search

Your search keyword '"Saenger, Yvonne"' showing total 210 results

Search Constraints

Start Over You searched for: Author "Saenger, Yvonne" Remove constraint Author: "Saenger, Yvonne" Database Unpaywall Remove constraint Database: Unpaywall
210 results on '"Saenger, Yvonne"'

Search Results

1. First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

2. Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation

3. Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States

4. Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients

5. 750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

7. Urine Proteomics Link Complement Activation with Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients

8. Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma

9. Supplemental Figure S3 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

10. Supplemental Methods from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

11. Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

12. Supplemental Figure Legends from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

13. Supplemental Figure S2 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

14. Data from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

15. Supplemental Figure S5 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

16. Supplemental Figure S1 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

17. Supplemental Methods from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

18. Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

19. Supplemental Figure S5 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

20. SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

21. Supplemental Figure S1 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

22. Supplemental Figure S4 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

23. Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

24. Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

25. Supplemental Figure Legends from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

26. Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

27. Supplemental Figure S4 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

28. Data from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

29. Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

30. Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

31. Supplemental Figure S2 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

32. SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

33. Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

34. Supplemental Figure S3 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

35. Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

36. Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma

37. Supplemental Table ST2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

38. Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

39. Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

40. Supplemental Figure S3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

41. Data from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma

42. Supplemental Table ST3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

43. Supplemental Table ST1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

44. Figure S3 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

45. Supplemental Table ST1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

46. Supplemental Figure Legends from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

47. Table S2 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

48. Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

49. Figure S2 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

Catalog

Books, media, physical & digital resources